Research LettersRegistration timelines of antiretroviral medicines in Ghana and KenyaAshigbie, Paul G.a; Laing, Richard O.a,b; Wirtz, Veronika J.a; Nkrumah, Nathanielc; Kemboi, Anthonyd; Nwokike, JudeeAuthor Information aDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA bSchool of Public Health, Faculty of Community Health Sciences, University of the Western Cape, Cape Town, South Africa cFood and Drugs Authority, Ghana dPharmacy and Poison Board, Kenya ePromoting the Quality of Medicines (PQM) Program, United States Pharmacopeial Convention, Rockville, Maryland, USA. Correspondence to Paul G. Ashigbie, Department of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA 02118, USA. Tel: +16173583046; E-mail: email@example.com Received 15 October, 2019 Accepted 10 February, 2020 AIDS: June 1, 2020 - Volume 34 - Issue 7 - p 1093-1095 doi: 10.1097/QAD.0000000000002514 Buy Metrics Abstract This study examines registration timelines of antiretroviral medicines (ARVs) in Ghana and Kenya, to assess whether prior reviews by the US Food and Drug Administration Tentative Approval or WHO prequalification (WHO/PQP) affect in-country approval timelines. Data were collected from online and national databases. Median in-country review period in Ghana was 9 months compared with 25 months in Kenya. ARVs with Tentative Approval and WHO/PQP status did not benefit from shorter in-country review periods. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.